NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 12:14PM ET
2.34
Dollar change
+0.06
Percentage change
2.41
%
Index- P/E- EPS (ttm)-0.89 Insider Own9.70% Shs Outstand266.14M Perf Week2.86%
Market Cap621.44M Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float240.33M Perf Month33.43%
Enterprise Value414.55M PEG- EPS next Q-0.23 Inst Own54.13% Short Float5.29% Perf Quarter50.65%
Income-238.13M P/S68.97 EPS this Y-4.42% Inst Trans-0.17% Short Ratio5.41 Perf Half Y1.52%
Sales9.01M P/B1.67 EPS next Y19.91% ROA-28.90% Short Interest12.71M Perf YTD-0.64%
Book/sh1.39 P/C1.20 EPS next 5Y19.72% ROE-49.97% 52W High5.00 -53.30% Perf Year-29.88%
Cash/sh1.95 P/FCF- EPS past 3/5Y24.01% 21.36% ROIC-35.06% 52W Low1.11 111.31% Perf 3Y-9.14%
Dividend Est.- EV/EBITDA- Sales past 3/5Y88.66% - Gross Margin-316.44% Volatility4.79% 6.77% Perf 5Y-85.10%
Dividend TTM- EV/Sales46.01 EPS Y/Y TTM25.80% Oper. Margin-2966.03% ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.99 Sales Y/Y TTM-14.16% Profit Margin-2642.69% RSI (14)69.00 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.21 EPS Q/Q-11.13% SMA205.72% Beta1.81 Target Price9.67
Payout- Debt/Eq0.84 Sales Q/Q-10.99% SMA5033.71% Rel Volume0.60 Prev Close2.28
Employees647 LT Debt/Eq0.83 EarningsMay 08 BMO SMA200-4.99% Avg Volume2.35M Price2.34
IPOJun 22, 2018 Option/ShortYes / Yes EPS/Sales Surpr.-6.78% 302.93% Trades Volume642,019 Change2.41%
Date Action Analyst Rating Change Price Target Change
Nov-18-24Upgrade Goldman Neutral → Buy $7 → $7.60
Nov-15-24Upgrade Redburn Atlantic Neutral → Buy $13
Nov-09-23Initiated Deutsche Bank Buy $10
Mar-27-23Resumed Wells Fargo Overweight $8
Mar-17-23Initiated Bryan Garnier Buy $5
Jun-14-21Upgrade Jefferies Hold → Buy $6 → $12
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Jun-24-25 05:34PM
12:52PM
Jun-20-25 03:00AM
Jun-12-25 02:00AM
May-29-25 04:05PM
08:30AM Loading…
May-23-25 08:30AM
May-20-25 01:52PM
May-14-25 09:30AM
May-09-25 03:20AM
May-08-25 07:00AM
May-07-25 06:00PM
12:36PM
11:09AM
Apr-26-25 12:15PM
Apr-25-25 12:06PM
04:05PM Loading…
Apr-23-25 04:05PM
Apr-22-25 07:00AM
Apr-16-25 01:00AM
Apr-02-25 08:40AM
07:00AM
Apr-01-25 07:00AM
Mar-21-25 12:03PM
03:03AM
01:44AM
Mar-20-25 11:56AM
11:55AM
07:00AM
Mar-19-25 06:00PM
Mar-06-25 07:00AM
04:49AM
07:00AM Loading…
Mar-05-25 07:00AM
Jan-17-25 07:00AM
Jan-13-25 07:00AM
Dec-30-24 02:43PM
Dec-09-24 07:30PM
Dec-05-24 07:12PM
Dec-02-24 07:00AM
Nov-19-24 06:11AM
Nov-15-24 02:03AM
Nov-13-24 02:09AM
02:03AM
Nov-12-24 07:00AM
Nov-11-24 04:19PM
02:23PM
12:53PM
07:12AM
07:04AM
Nov-08-24 04:23PM
Nov-05-24 09:00AM
Oct-28-24 05:00PM
Oct-17-24 02:29PM
Oct-16-24 09:00AM
08:58AM
Oct-09-24 05:37PM
Sep-19-24 07:00AM
Sep-12-24 04:18PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
Aug-27-24 07:00AM
Aug-08-24 07:00AM
Jul-26-24 07:00AM
Jun-14-24 07:00AM
Jun-13-24 02:31PM
May-31-24 08:00AM
May-19-24 08:09AM
May-18-24 02:42AM
May-17-24 01:52PM
07:42AM
07:00AM
May-14-24 10:00AM
May-13-24 11:15AM
07:00AM
Apr-24-24 10:00AM
Apr-23-24 07:00AM
Apr-02-24 07:00AM
Apr-01-24 07:00AM
Mar-21-24 01:43AM
Mar-17-24 09:19AM
Mar-15-24 05:53AM
Mar-14-24 01:51PM
07:00AM
Mar-12-24 07:00AM
Mar-11-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-12-24 02:29AM
Feb-08-24 07:00AM
06:07AM
05:45AM
Jan-23-24 07:00AM
Jan-22-24 07:00AM
Jan-10-24 07:00AM
Dec-22-23 07:00AM
Dec-18-23 02:58PM
Dec-09-23 08:30PM
Nov-27-23 07:00AM
Nov-15-23 07:00AM
Nov-06-23 07:00AM
Nov-05-23 05:34PM
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin PuleOfficerSep 16 '24Proposed Sale4.23698,7412,955,674Sep 16 05:02 PM